- Home
- GSIW vs RDHL Comparison
GSIW vs RDHL Comparison
Compare GSIW & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- RDHL
- Stock Information
- Founded
- GSIW 2016
- RDHL 2009
- Country
- GSIW Hong Kong
- RDHL Israel
- Employees
- GSIW N/A
- RDHL N/A
- Industry
- GSIW
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- GSIW
- RDHL Health Care
- Exchange
- GSIW Nasdaq
- RDHL Nasdaq
- Market Cap
- GSIW 8.1M
- RDHL 3.9M
- IPO Year
- GSIW 2023
- RDHL N/A
- Fundamental
- Price
- GSIW $0.13
- RDHL $1.51
- Analyst Decision
- GSIW
- RDHL
- Analyst Count
- GSIW 0
- RDHL 0
- Target Price
- GSIW N/A
- RDHL N/A
- AVG Volume (30 Days)
- GSIW 16.5M
- RDHL 88.5K
- Earning Date
- GSIW 01-01-0001
- RDHL 09-05-2025
- Dividend Yield
- GSIW N/A
- RDHL N/A
- EPS Growth
- GSIW N/A
- RDHL N/A
- EPS
- GSIW N/A
- RDHL N/A
- Revenue
- GSIW $5,368,221.00
- RDHL $9,550,000.00
- Revenue This Year
- GSIW N/A
- RDHL $381.91
- Revenue Next Year
- GSIW N/A
- RDHL N/A
- P/E Ratio
- GSIW N/A
- RDHL N/A
- Revenue Growth
- GSIW 283.23
- RDHL 157.62
- 52 Week Low
- GSIW $0.09
- RDHL $1.06
- 52 Week High
- GSIW $12.30
- RDHL $11.70
- Technical
- Relative Strength Index (RSI)
- GSIW 36.87
- RDHL 54.23
- Support Level
- GSIW $0.09
- RDHL $1.22
- Resistance Level
- GSIW $0.11
- RDHL $1.60
- Average True Range (ATR)
- GSIW 0.02
- RDHL 0.08
- MACD
- GSIW 0.03
- RDHL 0.04
- Stochastic Oscillator
- GSIW 40.05
- RDHL 76.32
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.